All Informatics articles – Page 4
-
ArticleThe predictive validity crisis: Pharma’s productivity paradox – Part I
Drug discovery now costs 100 times more per FDA-approved drug than in 1950, despite vast advances in biology and computing. The core problem is the collapse of predictive validity in preclinical models, which sits at the heart of pharma’s productivity paradox.
-
ArticleEye movements as objective biomarkers: accelerating CNS drug development
Measuring disease progression remains one of the biggest hurdles in CNS drug development. Eye movements, now trackable with just a laptop and webcam, are emerging as a sensitive and scalable biomarker that could transform how trials are designed and therapies reach patients.
-
NewsHow smoking and alcohol shape mutations in our DNA
Researchers have refined a cutting-edge DNA sequencing tool that reveals how mutations accumulate in healthy tissues as we age, offering insights into the earliest stages of cancer development.
-
NewsCloneSeq-SV: new blood test tracks ovarian cancer recurrence
Researchers have developed a new blood test method, CloneSeq-SV, that tracks treatment-resistant ovarian cancer cells over time. The approach could help predict recurrence and guide targeted therapies.
-
ArticleBeyond templates: advancing protein–protein interaction structure prediction with AI
Dr Alan Nafiiev evaluates template-based, docking and template-free approaches to PPI prediction, highlighting how AI can enhance structural accuracy.
-
ArticleFrom data to therapy: emerging tech driving cancer drug discovery
Multiomics, AI and liquid biopsies are giving researchers real-time insight into tumour biology and enabling more personalised cancer therapies. Find out how these technologies are advancing biomarker discovery, improving patient stratification, and guiding the design of new treatments.
-
ArticleMaking sense of AI: bias, trust and transparency in pharma R&D
AI is increasingly used in drug discovery, but hidden bias and ‘black box’ models threaten trust and transparency. This article explores how explainable AI can turn opaque predictions into clear, accountable insights.
-
ArticleAI meets human tissue to fast-track precision medicine development
By combining human tissue models with explainable AI, researchers can analyse complex patient data to identify which treatments work best for which patients. First applied to inflammatory bowel disease, this approach could improve clinical trial success rates across many diseases.
-
ArticleLab of the future: four technologies to watch
From precision proteomics to AI-powered immune profiling, next-generation laboratory technologies are changing how new therapies are discovered and developed. Here are four innovations set to shape the lab of the future - and the future of drug discovery.
-
ArticleAnimal-free drug discovery is closer with QSP
Quantitative Systems Pharmacology (QSP) is fast becoming a standard tool in drug development, offering a human-relevant way to predict drug effects before the clinic. Dr Josh Apgar of Certara explains how it is helping to cut reliance on animal testing and speed discovery.
-
NewsNew AI method maps how tuberculosis drugs destroy bacteria
Scientists at Tufts University have developed an AI tool that demonstrates how tuberculosis drugs kill bacteria – an advancement that could speed-up the discovery of shorter, more effective treatments.
-
ArticleBeyond the hype: a veteran’s honest assessment of AI in drug discovery – Part 3
AI is starting to transform drug discovery, but progress is still slow and big challenges remain. Thibault Géoui explores the gaps, hurdles and breakthroughs needed before it can truly change pharma R&D.
-
ArticleBeyond the hype: a veteran's honest assessment of AI in drug discovery - Part 2
Thibault Géoui explains why AI could finally help pharma overcome its productivity crisis and why the payoff won’t come as quickly as the optimists claim.
-
NewsStriosomes may hold the key to better treatments for mental disorders
Scientists have developed a new computational model that reveals how the striosomal compartment of the brain’s striatum influences decision-making – which could lead to improved therapies for psychiatric disorders.
-
ArticleBeyond the hype: a veteran’s honest assessment of AI in drug discovery - Part 1
An interview with Thibault Géoui reveals why this technology wave might finally break through pharma’s productivity crisis – and why it will take longer than the optimists claim.
-
WebinarOvercoming Affinity and Expression Bottlenecks in TCR Discovery
This expert-led webinar discusses how to break through common bottlenecks in TCR discovery with practical strategies that help teams move faster and smarter.
-
ArticleHow AI is quietly changing drug manufacturability
AI is moving beyond drug design to answer a critical question: can a promising compound actually be manufactured at scale? By predicting synthetic feasibility early, machine learning tools are helping drug developers avoid costly failures, streamline R&D and design molecules that are both effective and practical to produce.
-
ArticleManaging CGT trials: the role of IRT from discovery to clinical development
Discover how interactive response technology (IRT) is revolutionising the management of cell and gene therapy (CGT) trials by streamlining complex workflows, ensuring regulatory compliance and enhancing patient outcomes.
-
ArticleWhy smarter financial planning could be key to clinical trial success
Effective financial management is vital for clinical trial success, yet many preclinical and clinical companies face inefficiencies due to outdated systems. Jennifer Kyle, CEO of Condor Software, explains how advanced financial platforms can streamline processes, improve forecasting and ensure better resource allocation throughout drug development.
-
ArticleFixing failed drugs: AI solutions for toxicity in drug discovery – part 3
What role could large language models and AI agents play in drug safety? In Part 3, Layla Hosseini-Gerami of Ignota Labs discusses how emerging technologies might make toxicity analysis faster, more accessible and part of the drug discovery workflow from day one.